Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (61-70 of 231) with videos related to

Pageof 24
Sort By:
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
British Journal of Haematology|May 15, 2015
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosisMaria T Cibeira, Albert Oriol, Juan J Lahuerta, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignanciesPaul J Bröckelmann, Edward R Scheffer Cliff, Gloria Iacoboni, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
Annals of Hematology|October 15, 2016
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trialsMaria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
Leukemia & Lymphoma|January 3, 2023
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO studyHareth Nahi, Saad Z Usmani, Maria-Victoria Mateos, et al.
Pageof 24

Showing results (61-70 of 231) with videos related to

Sort By:
Pageof 24
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
British Journal of Haematology|May 15, 2015
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosisMaria T Cibeira, Albert Oriol, Juan J Lahuerta, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignanciesPaul J Bröckelmann, Edward R Scheffer Cliff, Gloria Iacoboni, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
Annals of Hematology|October 15, 2016
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trialsMaria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
Leukemia & Lymphoma|January 3, 2023
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO studyHareth Nahi, Saad Z Usmani, Maria-Victoria Mateos, et al.
Pageof 24